CCBR A/S
Ballerup Municipality, 2750, Denmark
NCT Number: NCT00486369
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin. Also the purpose is to assess the effect of different doses of oral calcitonin (0.6 mg and 0.8 mg oral) compared to placebo on serum CTX-I and CTX-II. Finally to assess the tolerance profile of different doses/formulations of oral calcitonin compared to placebo.
Looking for future studies?
Notify Me52 year–75 year
All sexes
Interventional
Phase 1
Ballerup Municipality, 2750, Denmark
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nordic Bioscience A/S
Industry
SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02108496
Arthritis, Joint Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT07720024
Arthritis, Blount disease
Pathum Thani, Changwat Pathum Thani, Thailand
View Trial DetailsNCT01818401
Arthritis, Joint Diseases
Nantes, France
View Trial DetailsNCT07710404
Arthritis, Joint Diseases
Faisalābad, Punjab Province, Pakistan
View Trial Details